Innovation strategy consultancy for life science-based companies and organisations: technology strategy, business development, due diligence, regulatory strategy; start-up and VC company support.
|Address:||45 St Barnabas Road, Cambridge|
|Membership type:||Professional Individual and Corporate < 5 (£50+VAT pa)|
BioBridge was founded in 1989 to help companies and organisations overcome the barriers to commercialisation for bioscience innovations. Mr Meredith Lloyd-Evans, founder and Managing Director, has 25 years' experience in animal, plant and human biotechnology and frontier healthcare, understanding and analysing technology in the commercial context.
He is the author of the Strategic Review of the UK's marine biotechnology activities, available at www.dti.gov.uk/sectors_biotechnology. He is also active in regulatory affairs and intellectual property strategy as well as carrying out market dynamics studies for innovative products.
He is a member of the Steering Group of ERBI Ltd; a founding partner of Arcadia International® eeig, Brussels Belgium, the specialist agrifood-chain strategists; Senior Associate of Managing Resources Ltd (www.managingresources.com); and a founder member of the international Association of Veterinary Consultants (www.avc.at).
Caroline Lloyd-Evans, HR and Training Director of BioBridge Ltd, has her own successful practice, CLE Consulting & Training, coaching and mentoring people in the workplace and in personal support, building better work-life balance and team dynamics. In today's high-pressure business environment, especially for start-ups and companies undergoing rapid expansion or downsizing, the best advantage needs to be taken of technology, business and people, and BioBridge provides analytical and practical support for this.
We understand the pressures that all companies in life sciences face, whether early-stage, SME or established. Market conditions and characteristics often create these pressures, but they are also imposed by the innovative nature of the product and technology base.
Our clients work in healthcare, medical devices, biomaterials and frontier medicine; food and agriculture; new micro- and nano-technologies with biomedical applications. We have helped them with business analysis and strategy, market analysis and dynamics, technology strategies, product and technology transfer, introductions and licensing, due diligence, regulatory affairs, product positioning, branding issues and employee and workplace dynamics management. We have:
A: moved technology prospects, start-ups and investment prospects forward:
- due diligence of a devices company prior to stock-market flotation, for a Japanese bank
- due diligence of an investment in novel cell-based treatments for Alzheimer's disease & bone dystrophies, for a regional investment agency
- due diligence of a genomic medicine services company, for a City firm of asset managers
- strategic advice to the chairmen and Boards of US companies developing new multi-use & needle-less syringes and new liver disease products
- start-up advice for device, diagnostic and trading companies
- critical analysis of biomaterials activity and end-use sectors in Scotland, for government
- IP and development advice during management of the European Biomaterials Network 1997-2000 for the EC, involving networking, communications, project audit and support for 19 multi-centre biomaterials and device projects.
B: enhanced company grasp of challenges for business growth and market management:
- analysis of markets for new burns and asthma treatments for a US company
- analysis of the market dynamics in Europe for cell-based liver support systems
- a European strategy for healthcare biomaterials and biopharmaceutical-device products
- regulatory dynamics in the EU for new fetal stem-cell based products
- compliance issues with live animal sources for medical device and cosmetics ingredients
- regulatory dynamics in the EU for a xenotransplantation product
- prospects for biopharmaceuticals from transgenic plants
- regulatory issues in Europe for GMOs in food, feed, farming and diagnostics
- acceptance strategies for anti-AIDS products in Spain
- the status of tissue engineering and regenerative medicine in Japan
- identifying and analysing licensable products for a Japanese pharmaceutical company
- analysing the biomaterials sector in Scotland, with a focus on international competitiveness and economic development
- strategic planning for exploitation of university inventions in biotechnology.
BioBridge's breadth of activity is made possible by Meredith's experience. After 4 years as a veterinarian in Canada and England, he joined SmithKline Animal Health UK Ltd and became Technical Director for UK and Co-ordinator for veterinary pharmaceutical product development in Europe. He then worked in technology transfer and licensing with the British Technology Group, responsible for a portfolio of inventors, patent applications, patents, development projects and commercial licenses in biotechnology, animal health and biomaterials. He worked briefly for PA Technology in biobusiness development before founding BioBridge. He is a member of the Licensing Executives' Society, ERBI Ltd, the UK BIA, the US BIO and the Organisation for Professionals in Regulatory Affairs, of which he has been a Board Director. He is a Fellow of the Royal Society of Arts, Manufactures and Commerce and a member of the Athenaeum; in April 2003, he was a member of the UK's Science Mission to Japan on Tissue Engineering and was an invited attendee at the first international Science & Technology in Society Forum, Kyoto Japan, in Autumn 2004, where he contributed to the working groups on Stem Cells and Research Mobility.
On Sunday 29th April, from 09.30 onwards, there will be a dog-walk at Childerley Hall, close to Cambridge, with financial support from Royal Canin. The Trust thanks Mr Martin Jenkins for allowing it to use the estate.
12 March 2012Read in full
Meredith Lloyd-Evans, Managing Director of BioBridge Ltd, joins The Institute of Advanced Study (IAS) at Durham University as Policy & Enterprise Fellow for the Michaelmas term 2011.
21 October 2011Read in full
BioBridge Ltd, the UK based consultancy, has been selected by IFAH, the International Federation for Animal Health, to manage its 2011 Global Benchmarking Survey, which is an update of IFAH’s 2006 survey.
18 May 2011Read in full
There are places still available for 'Biotechnology from Antarctica', an international conference on commercialising bioscience from the sea, which takes place in Cambridge on November 19th.
12 November 2009Read in full
BioBridge Ltd, the Cambridge-based independent life science innovation consultancy, was founded in 1989 and has been at the forefront of biotechnology and life science advances since then.
12 June 2009Read in full
BioBridge Ltd, the Cambridge-based life sciences innovation consultancy, is working with Bioscience for Business Knowledge Transfer Network to boost the UK’s industrial biotechnology in two major business-to-business activities in London in December, Biotechnology Business Exchange (8th December) and Genesis Conference (9th-10th December).
17 November 2008Read in full
Meredith Lloyd-Evans, founder and Managing Director of BioBridge Ltd, the Cambridge-based life sciences innovation consultancy, is supporting the Vet School’s Hope Appeal for its Christmas Festival at Michaelhouse, Cambridge on 10th December)
17 November 2008Read in full
Come and join BioBridge Ltd at Newmarket August 23rd to support the Cambridge Vet School new Linear Accelerator for treatment of pet cancer! Tickets £75 per person including champagne reception, lunch, afternoon tea, entry fee, race card for the entire day and entrance to the members’ enclosure. Details from Meredith 01223 566850 – a great day out!
29 July 2008Read in full
BioBridge Ltd, the Cambridge-based international life sciences consultancy, has produced a report 'Prospects for Marine Biotechnology in the UK', for the UK's Foresight Marine Panel Biotechnology Group, the Department of Trade and Industry and South West England Regional Development Agency.
8 February 2005Read in full